A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

BACKGROUND: Omarigliptin is a once-weekly (q.w.) oral DPP-4 inhibitor that is approved for the treatment of patients with type 2 diabetes mellitus (T2DM) in Japan. To support approval of omarigliptin in the United States, the clinical development program included a cardiovascular (CV) safety study....

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cardiovasc Diabetol
Huvudupphovsmän: Gantz, Ira, Chen, Menghui, Suryawanshi, Shailaja, Ntabadde, Catherine, Shah, Sukrut, O’Neill, Edward A., Engel, Samuel S., Kaufman, Keith D., Lai, Eseng
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2017
Ämnen:
Original Investigation
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5594521/
https://ncbi.nlm.nih.gov/pubmed/28893244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0593-8
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk